ECSP23020167A - Inhibidores de apol1 y métodos para usar los mismos - Google Patents

Inhibidores de apol1 y métodos para usar los mismos

Info

Publication number
ECSP23020167A
ECSP23020167A ECSENADI202320167A ECDI202320167A ECSP23020167A EC SP23020167 A ECSP23020167 A EC SP23020167A EC SENADI202320167 A ECSENADI202320167 A EC SENADI202320167A EC DI202320167 A ECDI202320167 A EC DI202320167A EC SP23020167 A ECSP23020167 A EC SP23020167A
Authority
EC
Ecuador
Prior art keywords
apol1
methods
inhibitors
tautomer
ndkd
Prior art date
Application number
ECSENADI202320167A
Other languages
English (en)
Inventor
John E Cochran
Elena Dolgikh
Leslie A Dakin
Jingrong Cao
Samantha Angle
Akira Joseph Shimizu
Brad D Maxwell
Hardwin O'dowd
Haoxuan Wang
Jon H Come
Steven David Stone
Suganthini S Nanthakumar
Timothy J Senter
Jun Myun Ahn
Jessica Howard Olsen
Michael Aaron Brodney
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of ECSP23020167A publication Critical patent/ECSP23020167A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona al menos una entidad elegida de los Compuestos de la Fórmula I, un tautómero del mismo, un derivado deuterado de ese compuesto o tautómero, y una sal farmacéuticamente aceptable de cualquiera de los anteriores, composiciones que comprenden los mismos, y métodos para usar los mismos, incluyendo los usos en el tratamiento de enfermedades mediadas por APOL1, incluyendo cáncer pancreático, glomeruloesclerosis segmentaria focal (FSGS), y/o enfermedad renal no diabética (NDKD).
ECSENADI202320167A 2020-08-26 2023-03-20 Inhibidores de apol1 y métodos para usar los mismos ECSP23020167A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063070705P 2020-08-26 2020-08-26

Publications (1)

Publication Number Publication Date
ECSP23020167A true ECSP23020167A (es) 2023-12-29

Family

ID=77822053

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202320167A ECSP23020167A (es) 2020-08-26 2023-03-20 Inhibidores de apol1 y métodos para usar los mismos

Country Status (20)

Country Link
US (1) US11866446B2 (es)
EP (1) EP4204423A1 (es)
JP (1) JP2023539194A (es)
KR (1) KR20230057386A (es)
CN (1) CN116547287A (es)
AR (1) AR123355A1 (es)
AU (1) AU2021333776A1 (es)
BR (1) BR112023003423A2 (es)
CA (1) CA3190609A1 (es)
CL (1) CL2023000536A1 (es)
CO (1) CO2023003026A2 (es)
CR (1) CR20230132A (es)
DO (1) DOP2023000042A (es)
EC (1) ECSP23020167A (es)
IL (1) IL300298A (es)
MX (1) MX2023002269A (es)
PE (1) PE20231106A1 (es)
TW (1) TW202227456A (es)
UY (1) UY39395A (es)
WO (1) WO2022047031A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019405477A1 (en) 2018-12-17 2021-06-24 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
CA3173808A1 (en) 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
AU2021333776A1 (en) 2020-08-26 2023-03-16 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
US20230119114A1 (en) * 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
WO2023141432A2 (en) 2022-01-18 2023-07-27 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2023154344A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
JP4028894B2 (ja) 1996-08-09 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾピペリジン誘導体
WO2001017965A2 (en) 1999-09-07 2001-03-15 Syngenta Participations Ag Cyanopiperidines as pesticides
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
AU2003237593A1 (en) 2002-06-05 2003-12-22 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
BRPI0507657A (pt) 2004-03-03 2007-07-10 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
JP5406722B2 (ja) 2006-10-16 2014-02-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ブラジキニン１受容体モジュレータとしての置換されたスルホンアミド誘導体
BRPI0721138A2 (pt) 2006-12-22 2014-04-01 Hoffmann La Roche Derivados de espiro-piperidina
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
JP5517935B2 (ja) 2007-08-17 2014-06-11 エルジー・ライフ・サイエンシーズ・リミテッド 細胞壊死阻害剤としてのインドール及びインダゾール化合物
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
UA107943C2 (en) 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
CA2781041C (en) 2009-11-16 2015-01-06 Eli Lilly And Company Spiropiperidine compounds as orl-1 receptor antagonists
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
WO2014085154A1 (en) 2012-11-27 2014-06-05 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
CA2959437C (en) 2014-08-27 2018-03-06 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
CA2967097A1 (en) 2014-11-21 2016-05-26 Laboratorios Del Dr. Esteve, S.A. Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain
RS61719B1 (sr) 2015-08-27 2021-05-31 Pfizer Biciklična fuzionisana hetaroaril ili aril jedinjenja kao modulatori irak4
WO2017137334A1 (en) 2016-02-08 2017-08-17 F. Hoffmann-La Roche Ag Spiroindolinones as ddr1 inhibitors
CA3103020A1 (en) 2018-04-30 2019-11-07 The Trustees Of Indiana University Compounds for modulating ddah and adma levels, as well as methods of using thereof to treat disease
AU2019405477A1 (en) 2018-12-17 2021-06-24 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2020186220A1 (en) 2019-03-13 2020-09-17 Immunophage Biomedical Co., Ltd. Compounds as inhibitors of macrophage migration inhibitory factor
US20230104936A1 (en) 2019-12-19 2023-04-06 Casma Therapeutics, Inc. Trpml modulators
AU2021213758A1 (en) 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021158666A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
CA3173808A1 (en) 2020-03-06 2021-09-10 Vertex Pharmaceuticals Incorporated Methods of treating apol-1 dependent focal segmental glomerulosclerosis
JP2023523176A (ja) 2020-04-22 2023-06-02 アニマ バイオテック インコーポレイテッド コラーゲン１翻訳阻害剤及びその使用方法
HUP2200468A1 (hu) 2020-04-29 2023-03-28 X Chem Zrt IAP antagonisták és gyógyászati alkalmazásuk
US20230201201A1 (en) 2020-05-07 2023-06-29 Rambam Med-Tech Ltd. Composition for use in the treatment of apol1-associated disease
MX2022015766A (es) 2020-06-12 2023-02-23 Vertex Pharma Formas sólidas del inhibidor de apol1 y uso de las mismas.
CN115867532A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1的抑制剂及其用途
AU2021286728A1 (en) 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and use of the same
AU2021333776A1 (en) 2020-08-26 2023-03-16 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
US20230119114A1 (en) 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same

Also Published As

Publication number Publication date
WO2022047031A1 (en) 2022-03-03
CO2023003026A2 (es) 2023-03-17
AU2021333776A1 (en) 2023-03-16
AR123355A1 (es) 2022-11-23
PE20231106A1 (es) 2023-07-19
IL300298A (en) 2023-04-01
KR20230057386A (ko) 2023-04-28
EP4204423A1 (en) 2023-07-05
CR20230132A (es) 2023-06-27
TW202227456A (zh) 2022-07-16
CA3190609A1 (en) 2022-03-03
US11866446B2 (en) 2024-01-09
CN116547287A (zh) 2023-08-04
DOP2023000042A (es) 2023-07-09
JP2023539194A (ja) 2023-09-13
MX2023002269A (es) 2023-05-16
US20220106327A1 (en) 2022-04-07
BR112023003423A2 (pt) 2023-03-21
UY39395A (es) 2022-03-31
CL2023000536A1 (es) 2023-09-08

Similar Documents

Publication Publication Date Title
ECSP23020167A (es) Inhibidores de apol1 y métodos para usar los mismos
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CR20190124A (es) Inhibidores de ssao de aminopirimidina
CL2021001561A1 (es) Inhibidores de apol1 y sus métodos de uso
CO2024000588A2 (es) Composiciones y métodos para la inhibición de ras
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
CO2020013840A2 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
CL2022000875A1 (es) Inhibidores del factor d del complemento para administración oral
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CO2022014272A2 (es) Agente para el tratamiento de lesión renal aguda inducida por medio de contraste
DOP2021000254A (es) Compuestos de pirrolidina
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
BR112022005706A2 (pt) Inibidores de 1,6-naftiridina substituída de cdk5
UY39799A (es) Compuestos de pirrolil–sulfonamida
AR057403A1 (es) 4- anilino-3-quinolincarbonitrilos para el tratamiento del cancer
CO2021017202A2 (es) Compuestos tricíclicos
AR125358A1 (es) Inhibidores heteroaromáticos bicíclicos de la peptidasa 5 relacionada con la calicreína (klk5)
AR126554A1 (es) Composiciones y métodos para la inhibición de ras
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
EA202192859A1 (ru) ПРОИЗВОДНЫЕ ТЕТРАГИДРО-1Н-ЦИКЛОПЕНТА[cd]ИНДЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА-2 (АЛЬФА), ИНДУЦИРУЕМОГО ГИПОКСИЕЙ